Skip to contentpdufa.bio

REVTORPYK (gedatolisib): FDA NDA 219908

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 219908 is the FDA application for REVTORPYK (gedatolisib). The FDA's Orange Book lists the applicant of record as CELCUITY INC and the first approval on it as Jul 14, 2026. Owner today: Celcuity Inc. (Nasdaq: CELC).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 219908 · Orange Book NDA 219908

Names for this drug

Brand name (FDA)REVTORPYK
Orange Book trade name: REVTORPYK
Active ingredient (FDA)GEDATOLISIB

Who holds the application

FDA applicant of recordCELCUITY INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayCelcuity Inc. (CELC)
Source: Celcuity press release, Jul 14, 2026
“MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing”

Products on NDA 219908 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001REVTORPYKPOWDER;INTRAVENOUS180MG/VIALJul 14, 2026

FDA decisions we track for this drug

Gedatolisib with Fulvestrant - (VIKTORIA-1)CELC · Decided

Drug page: /drug/gedatolisib

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.